bluebird bio Reports Certain Financial Statements Should No Longer Be Relied Upon And Substantial Doubt Regarding Its Ability To Continue As A Going Concern 

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or the “Company”) (NASDAQ: BLUE).

INVESTORS OF BLUEBIRD BIO STOCK WITH FINANCIAL LOSSES ARE ENCOURAGED TO CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C.

On March 26, 2024, bluebird bio reported that “[w]hen the Company files its Annual Report on Form 10-K for the year ended December 31, 2023. . ., it expects to continue to report that there is substantial doubt regarding its ability to continue as a going concern.”

bluebird bio also reported that “[o]n March 24, 2024, the Audit Committee of the Board of Directors . . .  of the Company, based on the recommendation of management and after consultation with [Ernst & Young LLP], concluded that the Company’s previously-issued audited consolidated financial statements for each fiscal year beginning January 1, 2019 and its previously-issued unaudited interim condensed consolidated financial statements for each of the first three quarters in such years, as well as the associated earnings releases and investor presentations or other communications describing such financial statements, were materially misstated and, accordingly, should no longer be relied upon.”

On this news, bluebird bio stock was down more than 13% at the open of the market on March 26, 2024.

BLUEBIRD BIO INVESTORS WITH FINANCIAL LOSSES ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE SECURITIES INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

bluebird bio Investors May Have Legal Claims - BLUE

SEND US A MESSAGE

5 + 11 =

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]